Pan-Cancer Analysis of BUB1B/hsa-miR-130a-3p Axis and Identification of Circulating hsa-miR-130a-3p as a Potential Biomarker for Cancer Risk Assessment


. 2022 Sep 22;2022:3261300.


doi: 10.1155/2022/3261300.


eCollection 2022.

Affiliations

Item in Clipboard

Xiaoxia Ding et al.


Evid Based Complement Alternat Med.


.

Abstract

Based on the fact that very little was found in the literature on the question of potential molecules and mechanism for high risk of cancer in patients with psoriasis, this study was designed and performed based on bioinformatics analysis including WGCNA. The most striking result to emerge from the data is that BUB1B/hsa-miR-130a-3p axis, closely related to the development of psoriasis, also plays a remarkable role in multiple cancer development. The expression patterns of hsa-miR-130a-3p were found significantly changed in multiple tumors, which was also associated with prognosis. Additionally, hsa-miR-130a-3p was downregulated in lesion skin of psoriasis, but there was no difference in blood between psoriasis patients and normal controls. Circulating has-miR-130a-3p was found to have a higher level of blood in multiple tumor patients, suggesting that hsa-miR-130a-3p has the potential to be a blood biomarker for cancer risk assessment in patients with psoriasis.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Figures


Figure 1



Figure 1

Flow chart.


Figure 2



Figure 2

Differentially expressed genes (DEGs) exploring. (a) Box plot before batch effect is removed. (b) Box plot before batch effect is removed. (c) Volcano plot of DEGs from PP-NN set. (d) Volcano plot of DEGs from PP-PN set. (e) Heatmap plot of top 50 DEGs from PP-NN set. (f) Heatmap plot of top 50 DEGs from PP-NN set. (g) Venn plot of overlapped DEGs between 2 sets. (PP: lesion skin from psoriasis patients; PN: no-lesion skin from psoriasis patients; NN: normal skin from normal controls).


Figure 3



Figure 3

The result of WGCNA. (a) The lowest power for scale independence. (b) Repeated hierarchical clustering tree. (c) The associations between clinic traits and the modules. (d) Scatter plot of GS and MM correlation between turquoise module and PP samples. (e) Venn plot of 697 hub genes from turquoise module and overlapped DEGs from the above 2 different comparisons.


Figure 4



Figure 4

Further analysis of hub DEGs. (a) Clusters from MCODE in Cytoscape. (b) Overlapped genes of 5 different methods from CytoHubba plugin in Cytoscape. (c) Expression pattern of 4 overlapped genes in merged dataset (GSE13355 and GSE14905). (d) Expression pattern of 4 overlapped genes in GSE78097. (e) Expression pattern of 4 overlapped genes in GSE55201.


Figure 5



Figure 5

Differentially expressed miRNAs (DEmiRNAs) exploring and analysis. (a) Volcano plot of DEmiRNAs from PP-NN set. (b) Volcano plot of DEmiRNAs from PP-PN set. (c) Venn plot of DEmiRNAs from the above 2 comparisons. (d) Results of disease enrichment analysis of overlapped DEmiRNAs from 2 sets using miEAA. (e) Results of KEGG enrichment analysis of overlapped DEmiRNAs from 2 sets using mirPath. (f) Upset plot of overlapped DEmiRNAs and predicted miRNAs targeting BUB1B using different online tools. (g and h) Expression pattern of hsa-miR-130a-3p in GSE142582 (g) and GSE55515 (h). Results of diseases enrichment analysis (i) and KEGG enrichment analysis (j) of hsa-miR-130a-3p using CancerMIRNome.


Figure 6



Figure 6

BUB1B expression pattern in pan-cancer; RNA expression pattern between normal and tumor samples (a) as well as paired tumor and normal tissues (b); protein expression pattern in pan-cancer using HPA database.


Figure 7



Figure 7

hsa-miR-130a-3p expression pattern in pan-cancer between normal and tumor samples ((a) figure from CancerMIRNome; (b) download dataset from TCGA) as well as paired tumor and normal tissues (c).


Figure 8



Figure 8

Association between the hsa-miR-130a-3p expression and OS in cancer patients. (a) A forest plot of hazard ratios of hsa-miR-130a-3p in 32 types of tumors. (b) Kaplan-Meier survival curves of OS for patients stratified by the different expressions of hsa-miR-130a-3p.


Figure 9



Figure 9

Correlations between the BUB1B and hsa-miR-130a-3p expression and the main pathological stages, including stage I, stage II, stage III, and stage IV.


Figure 10



Figure 10

Forest plot and ROC curve of hsa-miR-130a-3p expression in pan-cancer.


Figure 11



Figure 11

Correlations of coexpression for BUB1B/hsa-miR-130a-3p in pan-cancer.

Similar articles

References

    1. Karrys A., Rady I., Chamcheu R.-C. N. Bioactive dietary VDR ligands regulate genes encoding biomarkers of skin repair that are associated with risk for psoriasis. Nutrients . 2018;10(2):p. 174. doi: 10.3390/nu10020174.



      DOI



      PMC



      PubMed

    1. Lee J. H., Kim H. J., Han K. D. Cancer risk in 892 089 patients with psoriasis in Korea: a nationwide population-based cohort study. Journal of Dermatology . 2019;46(2):95–102. doi: 10.1111/1346-8138.14698.



      DOI



      PubMed

    1. Trafford A. M., Parisi R., Kontopantelis E., Griffiths C. E. M., Ashcroft D. M. Association of psoriasis with the risk of developing or dying of cancer. JAMA Dermatology . 2019;155(12):1390–1403. doi: 10.1001/jamadermatol.2019.3056.



      DOI



      PMC



      PubMed

    1. Vaengebjerg S., Skov L., Egeberg A., Loft N. D. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis. JAMA Dermatology . 2020;156(4):421–429. doi: 10.1001/jamadermatol.2020.0024.



      DOI



      PMC



      PubMed

    1. Chen M., Liao B., Li Z. Global similarity method based on a two-tier random walk for the prediction of microRNA–disease association. Scientific Reports . 2018;8(1):p. 6481. doi: 10.1038/s41598-018-24532-7.



      DOI



      PMC



      PubMed

Dies ist ein automatisch übersetzter Artikel. Er kann nur einer groben Orientierung dienen. Das Original gibt es hier: psoriasis

Schreibe einen Kommentar